Ossium Health is a technology company.
Ossium Health is focused on improving health, vitality, and longevity through bioengineering, particularly in cell therapy development using deceased donor transplants.
Ossium Health has raised $115.0M across 2 funding rounds.
Ossium Health has raised $115.0M in total across 2 funding rounds.
Ossium Health is a therapeutics company developing stem cell-based therapies by leveraging deceased donor bone marrow to treat blood cancers, immune diseases, organ transplant rejection, and musculoskeletal defects.[1][2][4][5] It serves patients with hematologic diseases, organ transplant recipients, and those needing bone repair through products like viable bone matrix allografts (OssiGraft™ and OssiGraft Prime™) and cell therapies such as hematopoietic progenitor cells (HPC, Marrow), mesenchymal stem cells (MSCs), and selected CD34+ cells.[2][4] The company solves critical shortages in high-quality stem cells for transplants, enabling better outcomes in blood/immune treatments and reducing lifelong immunosuppression after organ transplants, with strong growth shown by $125.4M in total funding, including a $52M recent round, and commercial products like OssiGraft™.[4][5]
Founded in 2016 in San Francisco, California, Ossium Health emerged from the need to harness deceased donor bone marrow—a vast, underutilized resource—for advanced cell therapies.[1][2][5] The founders recognized the potential in integrating the deceased donor transplant ecosystem with bioengineering to combat blood and immune diseases, creating the world's first bone marrow bank from deceased donors.[2][3][5] Early traction included collaborations like the 2021 partnership with ExCellThera to combine Ossium's donor stem cells with expansion technologies for blood cancers and organ tolerization, alongside partnerships with NMDP/Be The Match and Columbia University for clinical trials.[3][4]
Ossium rides the cell and gene therapy boom, addressing stem cell supply bottlenecks amid rising demand for personalized transplants in a $20B+ regenerative medicine market.[1][2] Timing aligns with advances in cryopreservation and organ procurement, amplified by post-pandemic focus on immune resilience and aging populations driving hematologic/organ failure cases.[4] Favorable forces include regulatory nods for donor-derived therapies and partnerships expanding access; Ossium influences the ecosystem by pioneering deceased donor integration, potentially lowering costs and scaling therapies beyond elite centers.[2][3]
Ossium's donor banking moat positions it for Phase 1 readouts in organ tolerance and GVHD trials, with OssiGraft™ commercialization signaling revenue ramps.[4][5] Trends like AI-optimized cell selection and combo therapies (e.g., with expansion tech) will accelerate growth, evolving Ossium into a bioengineering leader transforming transplants from risky procedures to routine cures—unlocking vitality for millions as in their mission.[2]
Ossium Health has raised $115.0M in total across 2 funding rounds.
Ossium Health's investors include ClimacticVC, First Round Capital, Manta Ray Ventures, Moonshots Capital, Pareto Holdings, Clark Landry, Logan Lorenz, Andreessen Horowitz, Animo Ventures, General Catalyst, NFX, Urban Innovation Fund.
Ossium Health has raised $115.0M across 2 funding rounds. Most recently, it raised $52.0M Series C in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $52.0M Series C | ClimacticVC, First Round Capital, Manta Ray Ventures, Moonshots Capital, Pareto Holdings, Clark Landry, Logan Lorenz | |
| Mar 1, 2021 | $63.0M Series B | Andreessen Horowitz, Animo Ventures, ClimacticVC, First Round Capital, General Catalyst, Manta Ray Ventures, Moonshots Capital, NFX, Pareto Holdings, Urban Innovation Fund, What If Ventures, Clark Landry, Logan Lorenz |